Pharmaceuticals News and Research

RSS

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

Genta Incorporated today announced financial results for the quarter and nine months ended September 30, 2009. The Company also announced a restructuring, reduction in workforce, and re-ordering of clinical development priorities.

16 Nov 2009

EntreMed announces financial results for the third quarter of 2009

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three- and nine-month periods ending September 30, 2009.

16 Nov 2009

Lack of hemophilia treatment in the developing world costing lives

When modern medicine finds a way to treat a medical condition, people often think that the problem is solved. But we also have to find ways to get that treatment into the hands of those who need it. For example, new research from North Carolina State University shows that much more needs to be done to help get existing treatment to hemophilia patients in the developing world, and that the current lack of treatment there is costing lives.

16 Nov 2009

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2009.

16 Nov 2009

Foreign particles in some products filled at Genzyme's Allston Landing facility, "Dear Doctor" letter issued

BioMarin Pharmaceutical Inc. announced today that Genzyme notified the company that, in rare circumstances, it has detected foreign particles in some products filled at the Allston Landing facility. To ensure that patients are not exposed to foreign particles during product administration, Genzyme has issued a "Dear Doctor" letter to all physicians treating patients with enzyme replacement products that it markets, including Aldurazyme.

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

ART Advanced Research Technologies receives delisting notice from TSX

ART Advanced Research Technologies Inc., a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, today announced that it will delay the release of its financial results for the third quarter ended September 30, 2009, considering the restructuring process that the company is currently undergoing.

16 Nov 2009

Researchers develop software tools to search and compare patient data at hospitals across Europe

By matching children with rare or life-threatening diseases and modelling potential disease progression, researchers hope to find new routes forward.

16 Nov 2009

Potential of the European Biomarker Analysis Market to be the focus at upcoming Analyst Briefing

The "omics" revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years. New biomarkers are discovered each day and this rapid development promises excellent growth potential for the biomarker analysis market. However, due to various challenges faced in biomarker validation and assay development, there is a huge lag between the time that a biomarker is discovered in the laboratory and the time it is actually commercialized.

16 Nov 2009

Simcere Pharmaceutical announces financial results for the third quarter of 2009

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported unaudited financial results for the quarter ended September 30, 2009.

16 Nov 2009

Patent number for Microfluidic Valve Mechanism received

Microfluidic Systems, a privately-held company, announced today that they received patent number 7,607,641, entitled "Microfluidic Valve Mechanism". This patent covers a broad set of claims regarding the integration of a diaphragm membrane into a rigid body of a cartridge functioning as both a fluidic seal and cover of the cartridge, and as a valve mechanism for fluidics control within the cartridge.

16 Nov 2009

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Following the completion of its merger with Schering-Plough, Merck today confirms and underscores its commitment to marketing and developing cardiovascular medicines for a range of cardiovascular disorders.

16 Nov 2009

Priority Review of the NDA for intravenous acetaminophen extended by three months

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Priority Review of the New Drug Application (NDA) for intravenous (IV) acetaminophen by three months.

15 Nov 2009

Tianyin Pharmaceutical reports 40.2% increase in revenues for the first quarter of fiscal 2010

Tianyin Pharmaceutical Co., Inc., a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced fiscal results for its first quarter ended September 30, 2009.

13 Nov 2009

Today's opinions and editorials

Unless you find more realistic ways of paying for the promises included in the bill, you are simply setting up the public for more frustration -- and yourselves for a political backlash (David Broder, 11/13).

13 Nov 2009

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Ore Pharmaceutical Holdings Inc. today reported financial results and provided an operational update for the third quarter ended September 30, 2009.

13 Nov 2009

M3 USA, Bristol-Myers Squibb to launch next-generation eLearning and eMarketing solution

M3 USA, together with Bristol-Myers Squibb, is launching a pilot program to oncologists using M3’s next-generation eLearning and eMarketing solution. The solution – M3 Messages™ – takes a new approach to developing valuable, long-term, online connections that help doctors stay current on advances in oncology.

13 Nov 2009

Kun Run Biotechnology net revenue increases 65% for the quarter ended September 30, 2009

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the third quarter ended September 30, 2009.

13 Nov 2009

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

Pro-Pharmaceuticals, Inc., a developer of galectin-targeted, carbohydrate therapeutic compounds to treat cancer and fibrosis, today reported its financial results for the third quarter and first nine months of fiscal 2009. These results are included in the Company’s Quarterly Report on Form 10-Q for the three- and nine-month periods ended September 30, 2009, which has been filed with the SEC.

13 Nov 2009

Third quarter 2009 financial results announced by Soligenix

Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today its financial results for the third quarter of 2009.

13 Nov 2009

Pharmaceuticals News and Research

Genta announces financial results for the third quarter of 2009, reduces workforce to cut payroll costs

EntreMed announces financial results for the third quarter of 2009

Lack of hemophilia treatment in the developing world costing lives

A.P. Pharma announces financial results for its third quarter ended September 30, 2009

Foreign particles in some products filled at Genzyme's Allston Landing facility, "Dear Doctor" letter issued

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

ART Advanced Research Technologies receives delisting notice from TSX

Researchers develop software tools to search and compare patient data at hospitals across Europe

Potential of the European Biomarker Analysis Market to be the focus at upcoming Analyst Briefing

Simcere Pharmaceutical announces financial results for the third quarter of 2009

Patent number for Microfluidic Valve Mechanism received

Merck to market and develop cardiovascular medicines for a range of cardiovascular disorders

Priority Review of the NDA for intravenous acetaminophen extended by three months

Tianyin Pharmaceutical reports 40.2% increase in revenues for the first quarter of fiscal 2010

Today's opinions and editorials

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

M3 USA, Bristol-Myers Squibb to launch next-generation eLearning and eMarketing solution

Kun Run Biotechnology net revenue increases 65% for the quarter ended September 30, 2009

Pro-Pharmaceuticals announces financial results for the third quarter and first nine months of fiscal 2009

Third quarter 2009 financial results announced by Soligenix

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring